Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer.

    The Company has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response to cancer. The Company’s programmes target the tumour microenvironment and exert their action through modulation, activation and/ or depletion of these immune cells.

    Tusk has a world-class leadership team as well as outstanding scientific advisors, including top immuno oncology researchers, and the team has extensive biotech and pharma experience in antibody discovery and drug development, with a track record of bringing drugs from early stage discovery through to approval.

    The Company is based at the Stevenage Bioscience Catalyst in Stevenage UK.